Diagnovus Reaches Deal to Commercialize EoE Assay | GenomeWeb

NEW YORK (GenomeWeb) – Molecular diagnostics firm Diagnovus announced today a licensing agreement with Cincinnati Children's Hospital Medical Center to commercialize a gene expression assay for the diagnosis of eosinophilic esophagitis (EoE).

The Engauge GI-EoE test, developed by researchers at the hospital, is the first genomic assay for diagnosing and treating EoE, Diagnovus said, adding it differentiates the ailment from gastroesophageal reflux disease (GERD) or chronic esophagitis.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.